Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Infectious diarrhea Stories

2011-12-07 09:36:21

(Ivanhoe Newswire) — Clostridium difficile is the most common cause of infectious diarrhea in the hospital, and these infections increase the length of stay in the hospital by six days. Researchers used The Ottawa Hospital Data Warehouse to analyze data on 136,877 admissions to The Ottawa Hospital between July 1, 2002 and March 31, 2009. A total of 1393 patients acquired C. difficile in hospital during this time, and these patients spent 34 days in hospital compared with 8 days for...

2011-10-20 07:00:00

SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that data being presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) demonstrate that patients treated with DIFICID(TM) (fidaxomicin) tablets for Clostridium difficile-associated diarrhea (CDAD) experienced faster resolution of diarrhea and lower risk of death during the first 12 days following initiation of treatment compared to patients treated with...

2011-10-13 07:00:00

SAN DIEGO, Oct. 13, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that new research findings for DIFICID(TM) (fidaxomicin) tablets will be featured in presentations at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) occurring October 20-23 in Boston. The presentations include one late-breaker highlighting a new analysis of combined results from Optimer's two large clinical studies of DIFICID for the treatment of Clostridium...

2011-09-23 07:00:00

SAN DIEGO, Sept. 23, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR(TM) (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea (CDAD). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) DIFICLIR,...

2011-09-09 09:02:00

SAN DIEGO, Sept. 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that 11 abstracts reporting new research findings for DIFICID(TM) (fidaxomicin) tablets will be presented at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place September 17-20 in Chicago. DIFICID was approved by the U.S. Food and Drug Administration (FDA) in May of 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18...

2010-10-11 07:00:00

SAN DIEGO, Oct. 11 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced two oral presentations from studies related to lead developmental product candidate, fidaxomicin, will be presented at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at the Vancouver Convention Center in Vancouver, British Columbia, Canada on October 21-24, 2010. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) (Logo:...

2010-04-06 07:00:00

SAN DIEGO, April 6 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria. (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO) "Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs....

2010-03-01 07:00:00

SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the Cowen and Company 30th Annual Health Care Conference at The Boston Marriott Copley Place on March 8, 2010, 4:00 p.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO) A live audio webcast of this presentation will be accessible on the Company's website at www.optimerpharma.com, under the investors section. A replay of this presentation...

2009-10-19 07:00:00

SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional data related to fidaxomicin, the Company's lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009. (Logo:...

2009-09-14 13:15:00

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the presentation of results from its second prulifloxacin Phase 3 clinical study for the treatment of infectious diarrhea in travelers, by clinical investigator Robert Steffen, M.D., at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO) Dr. Steffen presented the...